Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 70.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 70.
CONRAY vs OMNIPAQUE 70
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent